Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Receivables - Net: 2016-2022

Historic Receivables - Net for Summit Therapeutics (SMMT) over the last 7 years, with Dec 2022 value amounting to $349,000.

  • Summit Therapeutics' Receivables - Net fell 76.16% to $349,000 in Q4 2022 from the same period last year, while for Dec 2022 it was $349,000, marking a year-over-year decrease of 76.16%. This contributed to the annual value of $349,000 for FY2022, which is 76.16% down from last year.
  • Summit Therapeutics' Receivables - Net amounted to $349,000 in Q4 2022, which was up 149.29% from $140,000 recorded in Q3 2022.
  • Over the past 5 years, Summit Therapeutics' Receivables - Net peaked at $17.8 million during Q1 2019, and registered a low of $140,000 during Q3 2022.
  • Moreover, its 3-year median value for Receivables - Net was $870,000 (2022), whereas its average is $2.2 million.
  • Its Receivables - Net has fluctuated over the past 5 years, first skyrocketed by 835.62% in 2018, then tumbled by 96.43% in 2021.
  • Quarterly analysis of 5 years shows Summit Therapeutics' Receivables - Net stood at $16.6 million in 2018, then plummeted by 33.42% to $541,000 in 2019, then plummeted by 38.82% to $331,000 in 2020, then spiked by 342.30% to $1.5 million in 2021, then crashed by 76.16% to $349,000 in 2022.
  • Its last three reported values are $349,000 in Q4 2022, $140,000 for Q3 2022, and $238,000 during Q2 2022.